Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Oxford Biomedica Fundamentals

Company Name Oxford Biomedica Last Updated 29 Oct 2020
Industry Health Care Sector Pharmaceuticals
Shares in Issue (m) 82.22 Market Cap (£m) 670.94
PE Ratio -36.92 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -22.10 EPS Growth (%) -291.01
PEG 0.13 DPS Growth (%) n/a
Debt Ratio 19.53 Debt Equity Ratio 0.39
Net Gearing 25.26 Gross Gearing 38.48
Asset Equity Ratio 1.63 Cash Equity Ratio 21.48
Quick Ratio 1.88 Current Ratio 1.97
Price To Book Value 8.87 ROCE -22.23

Oxford Biomedica Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Oxford Biomedica Company Financials

Assets (£m) 2019 2018 2017
Tangible Assets 62 32 25
Intangible Assets 0 0 0
Investments 4 11 3
Total Fixed Assets 66 43 28
Stocks 3 4 3
Debtors 30 31 17
Cash & Equivalents 16 32 14
Other Assets 8 2 2
Total Assets 123 112 65
Liabilities (£m) 2019 2018 2017
Creditors within 1 year 29 29 22
Creditors after 1 year 18 49 37
Other Liabilities 0 0 0
Total Liabilities 47 78 59
Net assets 76 35 6
Equity (£m) 2019 2018 2017
Called up share capital 38 33 31
Share Premium 223 172 154
Profit / Loss -21 5 -12
Other Equity 2 4 4
Preference & Minorities 0 0 0
Total Capital Employed 76 35 6
Ratios 2019 2018 2017
Debt Ratio 19.53 58.59 85.92
Debt-to-Equity 0.39 0.63 0.63
Net Gearing 25.26 40.41 68.69
Gross Gearing 38.48 69.09 90.60
Assets / Equity 1.63 3.24 10.64
Cash / Equity 21.48 92.81 233.14
EPS -22.10 11.57 -0.29
Cash Flow (£m) 2019 2018 2017
Cash from operating activities -4 13 3
Cashflow before financing -23 3 1
Increase in Cash -16 18 -1
Income (£m) 2019 2018 2017
Turnover 64 67 38
Cost of sales 36 23 18
Gross Profit 28 44 19
Operating Profit -14 14 -6
Pre-Tax profit -21 5 -12
Profit / Loss for the year 38 33 31

Oxford Biomedica Company Background

Sector Pharmaceuticals
Activities Oxford BioMedica plc is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the Group) have built a sector leading lentiviral vector delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 430 people.
Latest Interim Date 17 Sep 2020
Latest Fiscal Year End Date 06 May 2020

Oxford Biomedica Directors

Appointed Director Position
2008-08-29 John Andrew Dawson Chief Executive Officer
2017-08-29 Stuart Paynter Chief Financial Officer
2016-02-01 Dr Lorenzo Tallarigo Non-Executive Chairman
2018-03-15 Dr Heather Elizabeth Preston Non-Executive Director
2016-06-01 Stuart Jonathon Brodie Henderson Non-Executive Director
2012-10-04 Martin Henry Diggle Non-Executive Director
2019-06-24 Robert Evgeniev Ghenchev Non-Executive Director
2010-01-01 Dr Andrew John William Heath Non-Executive Director

Oxford Biomedica Contact Details

Company Name Oxford Biomedica
Company Address Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA
Company Telephone +44 (0)1865 783 000
Company Website http://www.oxb.com/

Oxford Biomedica Advisors

Auditor Name PricewaterhouseCoopers LLP
Auditor Address 9 Greyfriars Road, Reading RG1 1JG.
Auditor Website http://www.pwc.co.uk/
Auditor Telephone +44 (0)
Registrar Name Link Asset Services
Registrar Address The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU.
Registrar Website http://www.linkassetservices.com/
Registrar Telephone 0870 162 3100
Broker Name Nomura Code Securities
Broker Address 1 Carey Lane, London, EC2V 8AE.
Broker Website http://www.nomuracode.com/
Broker Telephone +44 (0)20 7776 1200
Adviser Name Nomura Code Securities
Adviser Address 1 Carey Lane, London, EC2V 8AE.
Adviser Website http://www.nomuracode.com/
Adviser Telephone +44 (0)20 7776 1200
Solicitor Name Morrison & Foerster
Solicitor Address City Point, One Ropemaker Street, London EC2Y 9AW.
Solicitor Website http://www.mofo.com/
Solicitor Telephone +44 (0)20 920 4000
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a